ResearcherShanghai Jiao Tong UniversityNo recent work listed
Yu Wang
Matched on ORCID iD 0000-0002-8683-6196; OpenAlex author ID A5100445290. Sources: OpenAlex.
Their work
- Papers
- 4
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 18
2019: 1 paper · 2020: none · 2021: 2 papers · 2022: 1 paper
Papers 4
- Characterization of the genomic landscape in large-scale Chinese patients with pancreatic cancer. Co-author DOI 10.1016/j.ebiom.2022.103897↗
- Single-cell analysis of pancreatic ductal adenocarcinoma identifies a novel fibroblast subtype associated with poor prognosis but better immunotherapy response. Co-author DOI 10.1038/s41421-021-00271-4↗
- A phase I study of the safety and activity of K-001 in patients with advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12885-021-08375-6↗
- Patient-derived xenografts: a valuable platform for clinical and preclinical research in pancreatic cancer. Co-author DOI 10.21037/cco.2019.02.04↗
Closest collaborators
The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Jiujie Cui · 4 shared papers, 2019–2022 · strength 0.48
- Paper Patient-derived xenografts: a valuable platform for clinical and preclinical research in pancreatic cancer. DOI 10.21037/cco.2019.02.04↗
- Paper A phase I study of the safety and activity of K-001 in patients with advanced pancreatic ductal adenocarcinoma. DOI 10.1186/s12885-021-08375-6↗
- Paper Characterization of the genomic landscape in large-scale Chinese patients with pancreatic cancer. DOI 10.1016/j.ebiom.2022.103897↗
- Feng Jiao · 3 shared papers, 2021–2022 · strength 0.32
- Paper A phase I study of the safety and activity of K-001 in patients with advanced pancreatic ductal adenocarcinoma. DOI 10.1186/s12885-021-08375-6↗
- Paper Characterization of the genomic landscape in large-scale Chinese patients with pancreatic cancer. DOI 10.1016/j.ebiom.2022.103897↗
- Paper Single-cell analysis of pancreatic ductal adenocarcinoma identifies a novel fibroblast subtype associated with poor pro… DOI 10.1038/s41421-021-00271-4↗
- Tiebo Mao · 3 shared papers, 2021–2022 · strength 0.32
- Paper A phase I study of the safety and activity of K-001 in patients with advanced pancreatic ductal adenocarcinoma. DOI 10.1186/s12885-021-08375-6↗
- Paper Characterization of the genomic landscape in large-scale Chinese patients with pancreatic cancer. DOI 10.1016/j.ebiom.2022.103897↗
- Paper Single-cell analysis of pancreatic ductal adenocarcinoma identifies a novel fibroblast subtype associated with poor pro… DOI 10.1038/s41421-021-00271-4↗
- Jiong Hu · 3 shared papers, 2021–2022 · strength 0.32
- Paper A phase I study of the safety and activity of K-001 in patients with advanced pancreatic ductal adenocarcinoma. DOI 10.1186/s12885-021-08375-6↗
- Paper Characterization of the genomic landscape in large-scale Chinese patients with pancreatic cancer. DOI 10.1016/j.ebiom.2022.103897↗
- Paper Single-cell analysis of pancreatic ductal adenocarcinoma identifies a novel fibroblast subtype associated with poor pro… DOI 10.1038/s41421-021-00271-4↗
- Liwei Wang · 2 shared papers, 2019–2022 · strength 0.27
- Liwei Wang · 2 shared papers, 2021 · strength 0.21
- Paper A phase I study of the safety and activity of K-001 in patients with advanced pancreatic ductal adenocarcinoma. DOI 10.1186/s12885-021-08375-6↗
- Paper Single-cell analysis of pancreatic ductal adenocarcinoma identifies a novel fibroblast subtype associated with poor pro… DOI 10.1038/s41421-021-00271-4↗
- Xiaofei Zhang · 2 shared papers, 2021–2022 · strength 0.21
- Yongwei Sun · 2 shared papers, 2021–2022 · strength 0.21
- Jiayu Yao · 2 shared papers, 2021–2022 · strength 0.21
- Deliang Fu · 2 shared papers, 2021–2022 · strength 0.21
- Ting Han · 1 shared paper, 2021 · strength 0.11
- Haiyan Yang · 1 shared paper, 2021 · strength 0.11
- Yingbin Liu · 1 shared paper, 2022 · strength 0.11
- Weiyu Ge · 1 shared paper, 2022 · strength 0.11
- Yuexiang Wang · 1 shared paper, 2022 · strength 0.11
- Yiyi Liang · 1 shared paper, 2021 · strength 0.10
- Qing Xia · 1 shared paper, 2021 · strength 0.10
- Jing Xue · 1 shared paper, 2021 · strength 0.10
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.